Company Overview
- Website
- kanyos.com
- Phone
- (617) 674-9924(617) 674-9922
- Employees
- 16
- Founded in
- 2015
- Industry
- BioTech/Drugs
- NAICS Codes
-
32 - Manufacturing325 - Chemical Manufacturing3254 - Pharmaceutical and Medicine Manufacturing
- SIC Codes
-
28 - Chemicals and Allied Products283 - Drugs
Financials & Stats
Revenue
$3B
Total Funding Amount
$16M
Recent News & Media
Blood-based T Cell Diagnosis of Celiac Disease
- Jun 9, 2025
- sciencedirect.com
Dr Colby Souders – Twist Biopharma Solutions
- Apr 3, 2025
- wehi.edu.au
Standardizing Randomized Controlled Trials in Celiac Disease: An International Multidisciplinary Appropriateness Study
- Dec 1, 2024
- sciencedirect.com
Topas’ platform validated with top-line celiac disease data
- Oct 15, 2024
- bioworld.com
Topas says celiac candidate shines in phase 2a but keeps data under wraps for now
- Oct 15, 2024
- fiercebiotech.com
African Commodities Processing Ltd.
- Jul 24, 2024
- f6s.com
Who is Kanyos Bio
Kanyos Bio is a privately held company based in Cambridge, Massachusetts. The company employs 16 people and has generated $3.4 million in revenue. Kanyos Bio focuses on developing antigen-specific immune tolerance technology for the treatment of autoimmune diseases. Their primary targets are type-1 diabetes and celiac disease. The company leverages the immunotechnology expertise of its sister company, Anokion, and the clinical translation experience of Astellas Pharma, Inc. (“Astellas”). Kanyos Bio's technology originated at EPFL (Ecole Polytechnique Fédérale Lausanne) in Switzerland. For more information, visit kanyos.com.